Key result
RYGB linked to ~80% T2DM remission at one year regardless of baseline BMI.
Why the study?
Although bariatric surgery is commonly used to treat T2DM in morbidly obese patients, its efficacy in patients with BMI < 35 kg/m2 is not widely accepted despite promising evidence.
Does Roux-en-Y gastric bypass lead to similar rates of T2DM remission in patients with BMI < 35 kg/m2 compared to those with BMI > 35 kg/m2?
Cohort (n=112)
Does Roux-en-Y gastric bypass lead to similar rates of T2DM remission in patients with BMI < 35 kg/m2 compared to those with BMI > 35 kg/m2?
Roux-en-Y gastric bypass is highly effective in achieving laboratory remission of type 2 diabetes mellitus over 3 years, regardless of whether baseline BMI is above or below 35 kg/m2.
Answers are grounded in this paper and cite their sources.
Comparable T2DM remission after RYGB across BMI thresholds; extends observational evidence but leaves open randomized confirmation for lower-BMI patients.
INTRODUCTION: Bariatric surgery as treatment of type 2 diabetes mellitus (T2DM) in morbidly obese patients is becoming common. Although a large number of studies demonstrating high efficacy of bariatric methods in diabetics with body mass index (BMI) < 35 kg/m(2) have been published, this promising solution is still not accepted enough even in the era of a diabetes offensive. AIM: To analyze the dynamics of T2DM remission in patients with BMI < 35 kg/m(2) and > 35 kg/m(2) after Roux-en-Y gastric bypass (RYGB). MATERIAL AND METHODS: Data of 30 patients with BMI < 35 kg/m(2) and 82 with BMI > 35 kg/m(2) who underwent RYGB between 2007 and 2010 were collected from a prospectively designed database. The laboratory resolution of T2DM was determined by fasting plasma glucose (FPG ≤ 100 mg/dl) and glycosylated hemoglobin (HbA1c ≤ 6%). RESULTS: The T2DM regression was observed in 80% of the patients with BMI < 35 kg/m(2) and 83% in a group with BMI > 35 kg/m(2) 1 year after RYGB and about 80% 2 and 3 years after the operation in both groups. Normalization of average HbA1c and FPG was observed in the BMI > 35 kg/m(2) group after 3 months, while in the BMI < 35 kg/m(2) group it was reached 6 months postoperatively. Changes in main markers of T2DM were parallel with the BMI decrease 3-12 months after RYGB, but early resolution in some patients was observed independently of weight loss. CONCLUSIONS: The mid-term observation of patients after RYGB revealed the laboratory remission of T2DM. Ultimate evaluation of T2DM markers 3 years after surgery demonstrates high effectiveness of RYGB in managing T2DM in both groups.
No takes yet. Share an insight, caveat, or question.
Kaska et al. (2014) conducted a cohort in Type 2 diabetes mellitus (n=112). Roux-en-Y gastric bypass (RYGB) in BMI < 35 kg/m2 vs. Roux-en-Y gastric bypass (RYGB) in BMI > 35 kg/m2 was evaluated on Laboratory resolution of T2DM (fasting plasma glucose ≤ 100 mg/dl and glycosylated hemoglobin ≤ 6%) at 1 year. Roux-en-Y gastric bypass resulted in type 2 diabetes remission in 80% of patients with BMI < 35 kg/m2 and 83% of patients with BMI > 35 kg/m2 at 1 year, with sustained effects at 3 years.
Synapse has enriched 10 related papers. Consider them for comparative context: